Angiotensin II Blocks Nicotine-Mediated Neuroprotection against β-Amyloid (1-42) via Activation of the Tyrosine Phosphatase SHP-1

Journal of Neuroscience

Volumn 23, Issue 35, 2003, Pages 11224-11228

  Shaw, Seán ^a   Bencherif, Merouane ^b   Marrero, Mario B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TARGACEPT INC   (United States)

Author keywords

Alzheimer's disease; Ang II; JAK2; Neuroprotection; Nicotine; PC12 cells; Phosphatydylinositol 3 kinase; SHP 1

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; CHOLINERGIC ALPHA7 RECEPTOR; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINE; NICOTINIC RECEPTOR; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL STRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; HORMONE ACTION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR INTRINSIC ACTIVITY; SRC HOMOLOGY DOMAIN;

EID: 0346749449     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-35-11224.2003     Document Type: Article

References (22)

1. Ahmed ST, Ivashkiv LB (2000) Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 165:5227-5237.
2. Bencherif M, Lovette ME, Fowler KW, Arrington S, Reeves L, Caldwell WS, Lippiello PM (1996) RJR-2403: a nicotinic agonist with CNS selectivity. I. In vitro characterization. J Pharmacol Exp Ther 279:1413-1421.
3. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001) Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49:175-184.
4. de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL (1995) Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 47:164-171.
5. Dicou E, Attoub S, Gressens P (2001) Neuroprotective effects of leptin in vivo and in vitro. NeuroReport 12:3947-3951.
6. Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP (1996) In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 719:36-44.
7. Ge J, Barnes NM (1996) Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 297:299-306.
8. Horiuchi M, Akishita M, Dzau VJ (1998) Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocr Res 24:307-314.
9. Kem WR (2000) The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113:169-181.
10. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541-13546.
11. Kunioku H, Inoue K, Tomida M (2001) Interleukin-6 protects rat PC12 cells from serum deprivation or chemotherapeutic agents through the phosphatidylinositol 3-kinase and STAT3 pathways. Neurosci Lett 309:13-16.
12. Lehtonen JY, Daviet L, Nahmias C, Horiuchi M, Dzau VJ (1999) Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. Mol Endocrinol 13:1051-1060.
13. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC (1998) Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol 275:C1216-C1223.
14. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM (1996). Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648.
15. Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 49:268-278.
16. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J (2002) Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81:655-658.
17. Ryan RE, Ross SA, Drago J, Loiacono RE (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 132:1650-1656.
18. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F (2001) Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22:541-546.
19. Seo J, Kim S, Kim H, Park CH, Jeong S, Lee J, Choi SH, Chang K, Rah J, Koo J, Kim E, Suh Y (2001) Effects of nicotine on APP secretion and A. Biol Psychiatry 49:240-247.
20. Sharlow ER, Pacifici R, Crouse J, Batac J, Todokoro K, Wojchowski DM (1997) Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells. Blood 90:2175-2187.
21. Shaw S, Bencherif M, Marrero MB (2002) Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J Biol Chem 277:44920-44924.
22. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylchone receptor α7 subunits is an essential regulator of inflammation. Nature 421:384-388.